🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Steven Powell

Sanford Research

ORCID: 0000-0002-5029-0048

Biochemistry, Genetics and Molecular BiologyMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial”.

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00528-3

N/A

6.1DataRank · unranked

167 citations

Pavlos Msaouel, Kieko Hara, Haesun Choi, Venus Le, Amishi Y Shah +13 more

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine(2018)10.1056/nejmoa1801005

N/A

1.3DataRank · unranked

6524 citations

Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis +34 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps8598

N/A

0DataRank · unranked

1 citations

Austin W. Goodrich, Nathan R. Foster, Vinicius Ernani, Patrick M. Forde, Liza C. Villaruz +12 more

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps8603

N/A

0DataRank · unranked

1 citations

Austin W. Goodrich, Nathan R. Foster, Panos Savvides, Liza C. Villaruz, Patrick M. Forde +12 more

From Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World Evidence

medRxiv(2025)10.1101/2025.08.12.25333547

N/A

0DataRank · unranked

0 citations

Matthew J. Ferber, Sophie I. Candille, Ildiko Thibodeau, Daniela Iacoboni, Amy C. Sturm +15 more

592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0592

N/A

0DataRank · unranked

2 citations

Richard D. Carvajal, Diwakar Davar, Eduardo Castañón, Paolo A. Ascierto, Emiliano Calvo +16 more

The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications

Cancers(2021)10.3390/cancers13205206

N/A

0DataRank · unranked

95 citations

Lexi Vu, William C. Spanos, Dohun Pyeon, Steven Powell